TLC C-53 data

Results from a randomized, multicenter, double-blind, placebo-controlled Phase II study with TLC C-53 liposomal prostaglandin E1 in 25 patients with ARDS showed that on day eight, 8 of 17 patients treated with drug were able to be removed from a ventilator, while all 8 placebo patients required mechanical ventilation (p=0.03).

In addition, improvement in lung function efficiency, as measured by PaO2/FiO2 achieved statistical significance in treated patients by day 3, when the increase in PaO2/FiO2 from baseline was 82.5±14.6 in treated patients and 28.3±22.1 in the placebo group (p=0.05). ...